Pure Biologics Spólka Akcyjna (PUR.WA)

PLN 15.22

(-8.86%)

Total Liabilities Summary of Pure Biologics Spólka Akcyjna

Pure Biologics Spólka Akcyjna's latest annual total liabilities in 2023 was 20.84 Million PLN , up 41.69% from previous year.
Pure Biologics Spólka Akcyjna's latest quarterly total liabilities in 2024 Q2 was 17.49 Million PLN , down -23.04% from previous quarter.
Pure Biologics Spólka Akcyjna reported annual total liabilities of 14.71 Million PLN in 2022, up 90.97% from previous year.
Pure Biologics Spólka Akcyjna reported annual total liabilities of 7.7 Million PLN in 2021, down -64.71% from previous year.
Pure Biologics Spólka Akcyjna reported quarterly total liabilities of 22.72 Million PLN for 2024 Q1, up 9.03% from previous quarter.
Pure Biologics Spólka Akcyjna reported quarterly total liabilities of 20.84 Million PLN for 2023 Q4, down -60.03% from previous quarter.

Annual Total Liabilities Chart of Pure Biologics Spólka Akcyjna (2023 - 2016)

Historical Annual Total Liabilities of Pure Biologics Spólka Akcyjna (2023 - 2016)

Year	Total Liabilities	Total Liabilities Growth
2023	20.84 Million PLN	41.69%
2022	14.71 Million PLN	90.97%
2021	7.7 Million PLN	-64.71%
2020	21.82 Million PLN	49.8%
2019	14.57 Million PLN	234.41%
2018	4.35 Million PLN	290.25%
2017	1.11 Million PLN	74.43%
2016	640.12 Thousand PLN	0.0%

Year	Total Liabilities	Total Liabilities Growth
2024 Q2	17.49 Million PLN	-23.04%
2024 Q1	22.72 Million PLN	9.03%
2023 Q4	20.84 Million PLN	-60.03%
2023 Q1	42.67 Million PLN	190.07%
2023 FY	20.84 Million PLN	41.69%
2023 Q2	53.94 Million PLN	26.4%
2023 Q3	52.15 Million PLN	-3.31%
2022 Q4	14.71 Million PLN	148.68%
2022 Q3	5.91 Million PLN	-56.64%
2022 FY	14.71 Million PLN	90.97%
2022 Q2	13.64 Million PLN	-9.65%
2022 Q1	15.1 Million PLN	96.0%
2021 Q2	18.5 Million PLN	-4.38%
2021 FY	7.7 Million PLN	-64.71%
2021 Q4	7.7 Million PLN	-53.84%
2021 Q3	16.69 Million PLN	-9.81%
2021 Q1	19.35 Million PLN	-11.33%
2020 Q4	21.82 Million PLN	19.5%
2020 FY	21.82 Million PLN	49.8%
2020 Q3	18.26 Million PLN	-7.99%
2020 Q1	14.53 Million PLN	-0.27%
2020 Q2	19.85 Million PLN	36.61%
2019 Q2	6.23 Million PLN	-16.58%
2019 FY	14.57 Million PLN	234.41%
2019 Q4	14.57 Million PLN	67.48%
2019 Q3	8.7 Million PLN	39.53%
2019 Q1	7.47 Million PLN	71.55%
2018 Q3	1.51 Million PLN	0.0%
2018 FY	4.35 Million PLN	290.25%
2018 Q1	- PLN	-100.0%
2018 Q4	4.35 Million PLN	187.21%
2017 FY	1.11 Million PLN	74.43%
2017 Q4	1.11 Million PLN	0.0%
2016 FY	640.12 Thousand PLN	0.0%

Peer Total Liabilities Comparison of Pure Biologics Spólka Akcyjna

Name	Total Liabilities	Total Liabilities Difference
Bioceltix S.A.	2.26 Million PLN	-818.858%
BIOTON S.A.	215.86 Million PLN	90.344%
Captor Therapeutics Spolka Akcyjna	28.07 Million PLN	25.75%
Mabion S.A.	90.47 Million PLN	76.961%
Molecure S.A.	11.34 Million PLN	-83.742%
NanoGroup S.A.	1.49 Million PLN	-1298.902%
Pharmena S.A.	1.9 Million PLN	-993.652%
Poltreg S.A.	39.58 Million PLN	47.336%
Ryvu Therapeutics S.A.	120.36 Million PLN	82.681%
Synthaverse S.A.	153.26 Million PLN	86.399%
Urteste S.A.	1.85 Million PLN	-1023.72%